Promoting Learning from Null or Negative Results in Prevention Science Trials.

Evaluation Negative effect Null effect Randomized controlled trial

Journal

Prevention science : the official journal of the Society for Prevention Research
ISSN: 1573-6695
Titre abrégé: Prev Sci
Pays: United States
ID NLM: 100894724

Informations de publication

Date de publication:
07 2022
Historique:
pubmed: 5 8 2020
medline: 19 7 2022
entrez: 5 8 2020
Statut: ppublish

Résumé

There can be a tendency for investigators to disregard or explain away null or negative results in prevention science trials. Examples include not publicizing findings, conducting spurious subgroup analyses, or attributing the outcome post hoc to real or perceived weaknesses in trial design or intervention implementation. This is unhelpful for several reasons, not least that it skews the evidence base, contributes to research "waste", undermines respect for science, and stifles creativity in intervention development. In this paper, we identify possible policy and practice responses when interventions have null (ineffective) or negative (harmful) results, and argue that these are influenced by: the intervention itself (e.g., stage of gestation, perceived importance); trial design, conduct, and results (e.g., pattern of null/negative effects, internal and external validity); context (e.g., wider evidence base, state of policy); and individual perspectives and interests (e.g., stake in the intervention). We advance several strategies to promote more informative null or negative effect trials and enable learning from such results, focusing on changes to culture, process, intervention design, trial design, and environment.

Identifiants

pubmed: 32748164
doi: 10.1007/s11121-020-01140-4
pii: 10.1007/s11121-020-01140-4
pmc: PMC7398716
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

751-763

Subventions

Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

© 2020. The Author(s).

Références

JAMA Pediatr. 2018 Sep 1;172(9):807-809
pubmed: 30039164
CMAJ. 2006 Aug 15;175(4):347
pubmed: 16908892
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
Soc Sci Med. 2012 Dec;75(12):2299-306
pubmed: 22989491
Implement Sci. 2020 Jan 9;15(1):2
pubmed: 31915032
Prev Sci. 2015 Oct;16(7):893-926
pubmed: 25846268
Trials. 2018 Feb 17;19(1):116
pubmed: 29454390
Evaluation (Lond). 2019 Jan;25(1):23-45
pubmed: 30705608
Prev Sci. 2020 Jul;21(5):615-626
pubmed: 32240480
J Epidemiol Community Health. 2014 Mar;68(3):288-90
pubmed: 24336237
J Clin Child Adolesc Psychol. 2016 Nov-Dec;45(6):812-826
pubmed: 26566999
J Stud Alcohol Drugs. 2018 Mar;79(2):171-181
pubmed: 29553343
Cochrane Database Syst Rev. 2009 Jan 21;(1):MR000006
pubmed: 19160345
J Epidemiol Community Health. 2015 Jan;69(1):95-8
pubmed: 25403381
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
J Prim Prev. 2014 Aug;35(4):217-32
pubmed: 24753017
BMJ Qual Saf. 2016 May;25(5):303-10
pubmed: 26442789
J Epidemiol Community Health. 2019 Jun;73(6):481-482
pubmed: 30787038
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
Trials. 2018 Jul 31;19(1):406
pubmed: 30060763
Pilot Feasibility Stud. 2019 Mar 12;5:41
pubmed: 30923626
Lancet. 2014 Jan 11;383(9912):166-75
pubmed: 24411645
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
BMJ Open. 2018 Dec 19;8(12):e026906
pubmed: 30573493
J Child Psychol Psychiatry. 2017 Sep;58(9):1023-1032
pubmed: 28504358
Psychol Med. 2018 Nov;48(15):2453-2455
pubmed: 30070192
Clin Psychol (New York). 2016 Jun;23(2):180-200
pubmed: 29456295
Lancet Child Adolesc Health. 2018 Jan;2(1):35-45
pubmed: 29302609
Prev Sci. 2018 Apr;19(3):295-305
pubmed: 27106694
J Clin Epidemiol. 2017 Aug;88:92-101
pubmed: 28603008
Lancet Psychiatry. 2018 Feb;5(2):119-133
pubmed: 29307527
PLoS One. 2015 Aug 05;10(8):e0132382
pubmed: 26244868
Prev Sci. 2016 Oct;17(7):806-18
pubmed: 26453453
Prev Sci. 2021 Jan;22(1):100-112
pubmed: 32720189
J Child Psychol Psychiatry. 2018 Aug;59(8):829-830
pubmed: 29992597
BMJ. 2014 Jul 16;349:g4539
pubmed: 25030633
Eval Program Plann. 2015 Feb;48:124-31
pubmed: 25193177
Lancet. 2017 Dec 9;390(10112):2602-2604
pubmed: 28622953
BMJ Open. 2013 Aug 01;3(8):
pubmed: 23906953
Lancet. 2016 Jan 9;387(10014):146-55
pubmed: 26474809
BMJ Open. 2018 Feb 20;8(2):e017931
pubmed: 29463586

Auteurs

Nick Axford (N)

NIHR ARC South West Peninsula (PenARC), University of Plymouth, Plymouth, UK.

Vashti Berry (V)

NIHR ARC South West Peninsula (PenARC), University of Exeter, Exeter, UK. V.Berry@exeter.ac.uk.

Jenny Lloyd (J)

University of Exeter, Exeter, UK.

Tim Hobbs (T)

Dartington Service Design Lab, Dartington, UK.

Katrina Wyatt (K)

University of Exeter, Exeter, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH